UTILITY OF BONE MARROW ASPIRATION AND BIOPSY (BMAB) IN INITIAL STAGING OF EWING SARCOMA (EWS)

Post on 21-Mar-2016

64 views 1 download

Tags:

description

UTILITY OF BONE MARROW ASPIRATION AND BIOPSY (BMAB) IN INITIAL STAGING OF EWING SARCOMA (EWS). Lisa M. Kopp, Winston W. Huh, Cynthia E . Herzog, Chengcheng Hu, Andrea White-Collins, Beatriz Rozo , Angela Yarborough, Pooja Hingorani. Background. - PowerPoint PPT Presentation

Transcript of UTILITY OF BONE MARROW ASPIRATION AND BIOPSY (BMAB) IN INITIAL STAGING OF EWING SARCOMA (EWS)

UTILITY OF BONE MARROW ASPIRATION AND BIOPSY (BMAB) IN INITIAL STAGING

OF EWING SARCOMA (EWS)

Lisa M. Kopp, Winston W. Huh, Cynthia E. Herzog, Chengcheng Hu, Andrea White-Collins, Beatriz Rozo, Angela Yarborough, Pooja Hingorani

Background

• Pediatric and adolescents patients with newly diagnosed Ewing Sarcoma (EWS) have a bilateral bone marrow aspiration and biopsy (BMAB) performed as part of the initial staging evaluation

• BMAB is a painful procedure that is performed using general anesthesia

Background

• The NCCN guidelines on bone cancer recommend the option of either a BMAB or MRI of the spine and pelvis in newly diagnosed adult patients

• The necessity of a BMAB in staging pediatric and adolescent EWS patients in addition to radiological evaluation has not been previously established

Objectives

• To evaluate the association between imaging determined non-metastatic EWS and BM metastasis in pediatric and adolescent patients

• To evaluate the association between BM metastasis and other clinical characteristics of pediatric and adolescent EWS patients

Methods• Retrospective review involving 3 institutions

• Eligibility: Patients less than 40 years of age with newly diagnosed EWS between the years 2000-2012; available initial staging scans and BM evaluation

• 116 patients

• Initial staging reviewed– Imaging (MRI primary site, CT chest, Bone scan) – Bone Marrow Aspiration and Biopsy

Patient CharacteristicsNon-metastatic

(n=85) Metastatic (n=31)

Gender Male Female

47 (55.3%)38 (44.7%)

18 (58.1%)13 (41.9%)

Age at Diagnosis* 13 (1, 38) 16 (3, 25)Primary Tumor Site Pelvis Non-pelvis

15 (17.6%)70 (82.4%)

14 (45.2%)17 (54.8%)

Primary Tumor Size (cm)*, ** 7.5 (1.3, 26.0) 11.2 (3.5, 35.0)

* Median (range)** Primary tumor size of metastatic patients was significantly higher that that of non-metastatic patients (p-value = 0.017 by Wilcoxon rank-sum test)

Metastatic Patients

• Metastatic site:

• Patients with multiple metastatic sites:

Lung alone Bone alone BM alone Multiple

13 (41.9%) 2 (6.5%) 0 (0.0%) 16 (51.6%)

Lung Bone BM Lymph Nodes

9 (56.3%) 14 (87.5%) 13 (81.3%) 2 (12.5%)

BMAB Results

• None of the 85 non-metastatic patients determined by imaging had positive BMAB

• A positive pelvic primary site was not correlated with a positive bone marrowBMAB Correlation with pelvic primary site (n=116)

Pelvic Non-Pelvic P-value

BMAB positive 6 70.087

BMAB negative 23 80

BMAB Results

• 13 of 31 metastatic patients by imaging had positive BMAB

Number of Bony Metastatic Sites (bone scan, n=28)

BMAB positive BMAB negative P-value

3.5 (1.0, 11.0) 0.0 (0.0, 2.0) < 0.0001

Association of Metastasis by Imaging and BMAB

BMAB ResultsBone Metastasis Lung Metastasis

Yes No Yes No

Positive 12 1 6 7

Negative 4 14 16 2

P-value for association* 0.0002 0.017

*Fisher’s exact test was used to evaluate association.

Conclusion

• Pediatric and adolescent Ewing sarcoma patients with non-metastatic disease by imaging may have a bone marrow aspiration and biopsy eliminated as part of initial staging

• In patients with metastatic disease there is a high correlation between bone marrow metastasis and the number of bony metastatic sites

Acknowledgments

University of Arizona

• Phoenix Children’s Hospital– Pooja Hingorani, MD– Andrea White-Collins, NP

• University of Arizona – Mel and Enid Zuckerman College of Public Health– Chengcheng Hu, PhD

University of Texas MD Anderson Cancer Center Children’s Cancer Hospital

– Winston W. Huh, MD– Cynthia E. Herzog, MD, MPH– Beatriz Rozo, NP– Angela Yarbarough, NP